Results 221 to 230 of about 275,402 (290)

Towards a chemo-free approach for follicular lymphoma. [PDF]

Br J Haematol
Luminari S, Barbieri E, Nizzoli ME.
europepmc   +1 more source

Scaffold‐free three‐dimensional culture of chronic lymphocytic leukaemia preserves B–T‐cell cross‐talk and enables drug response profiling

British Journal of Haematology, Volume 209, Issue 3, Page 953-963, September 2026.
Summary Chronic lymphocytic leukaemia (CLL) presents a complex biological and clinical landscape, strongly influenced by the tumour microenvironment (TME). To better capture this heterogeneity, we have developed patient‐derived lymphoma spheroids from CLL samples (CLL‐PDLS), which recapitulate the cross‐talk between malignant cells and the autologous ...
Heribert Playa‐Albinyana, Ariadna Giró, Juan A. Piñeyroa, Ferran Araujo‐Ayala, Cèlia Dobaño‐López, Sara Otín‐Sánchez, Elías Campo, Christine Bezombes, Patricia Pérez‐Galán, Dolors Colomer   +9 more
wiley   +1 more source

Favre Racouchot Disease as a Side Effect of Cutaneous Lymphoma Radiotherapy

JEADV Clinical Practice, Volume 5, Issue 3, Page 998-999, September 2026.
Anis Saad, Joi Carter
wiley   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, Volume 209, Issue 3, Page 874-886, September 2026.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations. [PDF]

Cancers (Basel)
Shpitzer D, Perry C, Shragai T, Melamed G, Smith MR, Vitkon R, Alapi H, Avivi I.   +7 more
europepmc   +1 more source

Effects of chronic lymphocytic leukaemia (CLL)‐directed therapy on diffuse large B‐cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort

British Journal of Haematology, Volume 209, Issue 3, Page 1020-1030, September 2026.
Summary Diffuse large B‐cell lymphoma (DLBCL) type Richter transformation (DLBCL‐RT) in patients with chronic lymphocytic leukaemia (CLL) has a worse prognosis compared to de novo DLBCL (dnDLBCL). We investigated outcomes of patients with DLBCL‐RT with or without previous CLL‐directed therapy compared to dnDLBCL between 2002 and 2022.
Andreas Katsimigas, Mikkel Werling, Casper M. Frederiksen, Noomi Vainer, Klaus Rostgaard, Yasmin Ben‐Dali, Mariam H. Hleuhel, Christian Brieghel, Carsten U. Niemann, Caspar da Cunha‐Bang   +9 more
wiley   +1 more source

Sequencing Cellular Therapies in the Management of Follicular Lymphoma. [PDF]

Cells
Jóna Á, Illés Á.
europepmc   +1 more source

Study on the expression of lactate transport-related proteins in follicular lymphoma and their relationship with clinicopathologic features. [PDF]

Front Cell Dev Biol
Xu Z, Wang X, Li J, Zhang X, Wang X.
europepmc   +1 more source

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma. [PDF]

Blood Adv
Iacoboni G, Kyvsgaard ER, Navarro Garcés V, Russler-Germain DA, Lewis K, Martín García-Sancho A, Carro I, Thompson PA, Therwhanger D, Quintela D, Ku M, Gómez P, Valencia E, Vega G, Jiménez-Ubieto A, Bastos-Oreiro M, Serna A, Husby S, De La Cruz B, Luan J, Camarillas S, Medina L, Cabero A, Córdoba R, Canales M, Sancho JM, Bosch F, Sureda A, Schuster S, Cheah CY, Hutchings M, Barba P, Abrisqueta P.   +32 more
europepmc   +1 more source